EP1931646A2 - Antagonistes cgrp selectionnes, leur procede de fabrication et leur utilisation comme medicaments - Google Patents

Antagonistes cgrp selectionnes, leur procede de fabrication et leur utilisation comme medicaments

Info

Publication number
EP1931646A2
EP1931646A2 EP06793855A EP06793855A EP1931646A2 EP 1931646 A2 EP1931646 A2 EP 1931646A2 EP 06793855 A EP06793855 A EP 06793855A EP 06793855 A EP06793855 A EP 06793855A EP 1931646 A2 EP1931646 A2 EP 1931646A2
Authority
EP
European Patent Office
Prior art keywords
alkylene
alkyl
general formula
compounds
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06793855A
Other languages
German (de)
English (en)
Inventor
Stephan Georg Mueller
Klaus Rudolf
Philipp Lustenberger
Gerhard Schaenzle
Dirk Stenkamp
Henri Doods
Kirsten Arndt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim International GmbH
Priority to EP06793855A priority Critical patent/EP1931646A2/fr
Publication of EP1931646A2 publication Critical patent/EP1931646A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to the CGRP antagonists of general formula I.
  • R 1 , R 2 , R 3 , R 4 and R 5 are as defined in claim 1, their tautomers, their isomers, their diastereomers, their enantiomers, their hydrates, their mixtures and their salts and the hydrates of the salts, in particular their physiologically acceptable salts with inorganic or organic acids or bases, as well as those compounds of the general formula I in which one or more hydrogen atoms are replaced by deuterium, medicaments containing these compounds, their use and processes for their preparation.
  • R 1 is a group selected from
  • R is a group of the general formulas II
  • R 1 is H, halogen, C 1-3 alkyl-O, C 1-3 alkyl or F 3 C-, R 2 - 2 H, H 2 N, HO-, H 3 CO-, HC (O) -O- or C 1-3 -alkyl-C (O) -O-,
  • R 2 - represents 3 H, halogen, C 1-3 -alkyl- or F 3 C-,
  • R 3 is a group of the general formulas III
  • R 3 - 1 H C 1-3 -alkyl or R 3 / M - (O) C-,
  • R 3 is 2 H or C 1-3 alkyl when X is C
  • R 4 is a group selected from
  • R 5 D- ⁇ -alkyl, phenyl, pyridyl-C 1-3 alkylene- 1 H indanyl, HO-C 2 - 4 alkylene, C 1-6 alkyl-OC 2-4 -alkylene-, HO-C 2-4 -alkylene-OC 2-4 -alkylene, C 1-6 -alkyl-C 2-4 -alkylene-OC 2-4 -alkylene-, H 2 NC 2-4 - alkylene, (C 1-6 alkyl) -NH-C 2-4 alkylene, (C 1-6 alkyl) 2 NC 2-4 alkylene, H 2 NC (O) -C 1-3 alkylene, (C 1-6 alkyl) -NH-C (O) -C 1-3 alkylene, (C 1-6 alkyl) 2 NC ( O) -C 1-3 -alkylene, C 1-6 -alkyl-C (O) -OC 1-3 -alkylene, C 1-6
  • a second embodiment of the present invention consists in the compounds of the above general formula I, in which
  • R 1 is a group selected from
  • R 1.1 represents H or H 3 CO-
  • R 2 is a group selected from
  • R 3 -R 4 together form a group selected from
  • R 5.1 is H, C 1-8 alkyl, phenyl, indanyl, pyridyl-C 1-3 -alkylene, HO-C 2 - 4 alkylene, C 1-6 alkyl-OC 2-4 - alkylene, HO-C 2 - 4 -alkylene-OC 2 - 4 -alkylene, C 1-6 -alkyl-C 2-4 -alkylene-OC 2-4 -alkylene, H 2 NC 2-4 -alkylene -, (C 1-6 -alkyl) -NH-C 2-4 -alkylene, (C 1-6 -alkyl) 2 NC 2-4 -alkylene, H 2 NC (O) -C 1-3 - alkylene, (C 1-6 alkyl) -NH-C (O) C 1-3 alkylene, (C 1-6 alkyl) 2 NC (O) C 1-3 alkylene, C 1-6 -alkyl-C (O) -OC 1-3
  • R 5.1 .1 a group selected from
  • a third embodiment of the present invention consists in the compounds of the above general formula I, in which
  • R 1 is a group selected from
  • R 3 -R 4 together form a group selected from
  • R 5.1 is H, C 1-6 -alkyl, phenyl, indanyl, pyridyl-CH 2 -, C 1-3 -alkyl-OC 2-4 -alkylene, C 1-3 -alkyl-OC 2-4 -alkylene-OC 2-4 -alkylene, (C 1-3 -alkyl) 2 NC 2 - 4 -alkylene-, (C 1-3 -alkyl) 2 NC (O) -C 1-3 -alkylene-, C 1-6 -alkyl-C (O) -OC 1-3 -alkylene, C 1-3 -alkyl-OC (O) -OC 1-3 -alkylene, R 5.1.1 -C (O) - C 1-3 alkylene- or R 5.1.2 -C 2 - 4 alkylene,
  • R 5.1.1 a group selected from
  • substituents are independent of each other. If a group, for example more C 1-6 -alkyl groups as substituents, as in the case of three substituents C1-6 alkyl may independently of one another once methyl, one n-propyl and one tert-butyl. In the context of this application, in the definition of possible substituents, these can also be represented in the form of a structural formula. As used herein, an asterisk ( * ) in the structural formula of the substituent is understood to be the point of attachment to the remainder of the molecule.
  • the compounds of the invention including their salts, in which one or more hydrogen atoms, for example one, two, three, four or five hydrogen atoms, are replaced by deuterium.
  • C 1-3 -alkyl (including those which are part of other radicals) are to be understood as meaning branched and unbranched alkyl groups having 1 to 3 carbon atoms, branched and unbranched alkyl groups having 1 to 3 by the term “C 1-6 -alkyl” 6 and understood by the term “d- ⁇ -alkyl” branched and unbranched alkyl groups having 1 to 8 carbon atoms.
  • Examples include: methyl, ethyl, n-propyl, / so-propyl, n-butyl, / so-butyl, sec-butyl, terf-butyl, n-pentyl, / so-pentyl, neo-pentyl, hexyl, Heptyl or octyl.
  • the abbreviations Me, Et, n-Pr, / -Pr, n-Bu, / -Bu, t-Bu, etc. are also used for the abovementioned groups.
  • propyl, butyl, pentyl, hexyl, heptyl and octyl include all conceivable isomeric forms of the respective radicals.
  • propyl includes n-propyl and / so-propyl
  • butyl includes / so-butyl, sec-butyl and tert-butyl, etc.
  • C 1-3 -alkylene (even if they are part of other radicals) are branched and unbranched alkylene groups having 1 to 3 carbon atoms and the term “C 2 - 4 -alkylene” branched and unbranched alkylene groups having 2 to 4 Understood carbon atoms.
  • propylene and butylene include all conceivable isomeric forms of the same carbon number.
  • propylene also includes 1-methylethylene and butylene includes 1-methyl-propylene, 1, 1-dimethylethylene, 1, 2-dimethylethylene.
  • Halogen in the context of the present invention is fluorine, chlorine, bromine or iodine. Unless otherwise indicated, fluorine, chlorine and bromine are preferred halogens.
  • Compounds of general formula I may have acid groups, mainly carboxyl groups, and / or basic groups such as e.g. Amino functions.
  • Compounds of general formula I can therefore be used as internal salts, as salts with pharmaceutically usable inorganic acids such as hydrobromic acid, phosphoric acid, nitric acid, hydrochloric acid, sulfuric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid or organic acids such as malic acid, succinic acid, Acetic acid, fumaric acid, maleic acid, mandelic acid, lactic acid, tartaric acid, citric acid or as salts with pharmaceutically usable bases such as alkali metal or alkaline earth metal hydroxides, for example sodium hydroxide or potassium hydroxide, or carbonates, ammonia, zinc or ammonium hydroxides or organic amines such as Diethylamine, triethylamine
  • the invention relates to the respective compounds optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates, in the form of tautomers and in the form of the free bases or the corresponding acid addition salts with pharmacologically acceptable acids - such as acid addition salts with hydrohalic acids - for example chlorine or hydrobromic acid - or organic acids - such as oxalic, fumaric, diglycolic or methanesulfonic acid
  • pharmacologically acceptable acids - such as acid addition salts with hydrohalic acids - for example chlorine or hydrobromic acid - or organic acids - such as oxalic, fumaric, diglycolic or methanesulfonic acid
  • the compounds of the invention may exist as racemates if they possess only one chiral element, but they may also be present as pure enantiomers, i. in (R) or (S) form. Preference is given to compounds which are present as racemates or as (R) -form.
  • the application also includes the individual pairs of diastereomeric antipodes or mixtures thereof which are present when more than one chiral element is present in the Compounds of the general formula I is present, as well as the individual optically active enantiomers, from which the mentioned racemates are composed.
  • the invention relates to the respective compounds optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates, in the form of tautomers and in the form of the free bases or the corresponding acid addition salts with pharmacologically acceptable acids - such as acid addition salts with hydrohalic acids - for example chlorine or hydrobromic acid - or organic acids - such as oxalic, fumaric, diglycolic or methanesulfonic acid.
  • pharmacologically acceptable acids - such as acid addition salts with hydrohalic acids - for example chlorine or hydrobromic acid - or organic acids - such as oxalic, fumaric, diglycolic or methanesulfonic acid.
  • the compounds of general formula I are prepared by methods known in principle. The following processes have proved particularly suitable for the preparation of the compounds of general formula I according to the invention:
  • the coupling is preferably carried out using methods known from peptide chemistry (see, for example, Houben-Weyl, Methoden der Organischen Chemie, Vol. 15/2), where, for example, carbodiimides, such as, for example, Dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC) or ethyl (3-dimethylamino-propyl) -carbodiimide, O- (1 / - / - benzotriazol-1-yl) - / V, / V- / V, / V tetramethyluronium hexa-fluorophosphate (HBTU) or tetrafluoroborate (TBTU) or 1H-benzotriazol-1-yl-oxy-tris (dimethylamino) phosphonium hexafluorophosphate (BOP).
  • DEC Dicyclohexylcarbodiimide
  • DIC di
  • the reaction rate can be increased by adding 1-hydroxybenzotriazole (HOBt) or 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine (HOObt).
  • HOBt 1-hydroxybenzotriazole
  • HEObt 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine
  • the couplings are normally used with equimolar proportions of the coupling components as well as the coupling reagent in
  • Solvents such as dichloromethane, Tetra h yd rofu ran, acetonitrile, dimethylformamide (DMF), dimethylacetamide (DMA), ⁇ / -methylpyrrolidone (NMP) or mixtures thereof and at temperatures between -30 ° C and + 30 ° C, preferably -20 ° C and + 25 ° C, performed. If necessary, als / ethyldiisopropylamine (Hünig base) is preferred as additional auxiliary base.
  • R 1 and R 2 are defined as mentioned above and Nu is a leaving group, for example a halogen atom, such as the chlorine, bromine or iodine atom, an alkylsulfonyl oxy devis having 1 to 10 carbon atoms in the alkyl moiety, optionally by chlorine or bromine atoms, by Methyl- or nitro groups mono-, di- or trisubstituted phenylsulfonyloxy or naphthylsulfonyloxy group, where the substituents may be identical or different, a 1 / - / imidazol-1-yl, optionally substituted by one or two methyl groups in the carbon skeleton 1 H-pyrazol-1-yl, a 1 H-1, 2,4-triazol-1-yl, 1 / - / - 1, 2,3-triazol-1-yl, 1 / - / - 1, 2,3,4-tetrazol-1-yl, a vinyl
  • any carboxylic acid functions, primary or secondary amino functions or hydroxyl functions which may be present in the radicals of the general formula V may be protected by conventional protecting groups and any protecting groups used may be cleaved off after the reaction has been carried out by methods familiar to the person skilled in the art.
  • the reaction is under Schotten-Baumann or Einhorn conditions carried out, that is, the components in the presence of at least one equivalent of an auxiliary base at temperatures between -50 ° C and + 120 ° C, preferably from -10 0 C and + 30 ° C, and optionally reacted in the presence of solvents.
  • auxiliary bases are alkali metal and alkaline earth metal hydroxides, for example sodium hydroxide, potassium hydroxide or barium hydroxide, alkali metal carbonates, eg. As sodium carbonate, potassium carbonate or cesium carbonate, alkali metal acetate, for example sodium or potassium acetate, and tertiary amines, for example pyridine, 2,4,6-trimethylpyridine, quinoline, triethylamine, ⁇ / -Ethyldiisopropylamin, ⁇ / -Ethyldicyclohexylamin, 1, 4 Di-azabicyclo [2,2,2] octane or 1,8-diazabicyclo [5,4,0] undec-7-ene as solvent, for example dichloromethane,
  • novel compounds of the general formula I according to the invention contain one or more chiral centers. For example, if there are two chiral centers, then the compounds can be in the form of two diastereomeric antipode pairs.
  • the invention includes the individual isomers as well as their mixtures.
  • the separation of the respective diastereomers is possible due to their different physicochemical properties, e.g. by fractional crystallization from suitable solvents, by high pressure liquid or column chromatography using chiral or preferably achiral stationary phases.
  • racemates which contain a basic or acidic function can also be separated via the diastereomeric, optically active salts which, when reacted with an optically active acid, for example (+) - or (-) - tartaric acid, (+) - or ( -) - diacetyltartaric acid, (+) - or (-) - monomethyl tartrate or (+) - or (-) - camphorsulfonic acid, or an optically active base, for example with (R) - (+) - 1-phenylethylamine, (S) - (-) - 1-phenylethylamine or (S) -brucine.
  • an optically active acid for example (+) - or (-) - tartaric acid, (+) - or ( -) - diacetyltartaric acid, (+) - or (-) - monomethyl tartrate or (+) - or (-) - camphorsulfonic acid, or an optically active base, for example
  • the racemate of a compound of the general formula I is reacted with one of the abovementioned optically active acids or bases in an equimolar amount in a solvent and the resulting crystalline, diastereomeric, optically active salts are separated by utilizing their different solubilities.
  • This reaction can be carried out in any kind of solvents as long as they have a sufficient difference in the solubility of the salts.
  • methanol, ethanol or mixtures thereof, for example in the volume ratio 50:50 are used.
  • each of the optically active salts is dissolved in water with a base such as sodium carbonate or potassium carbonate, or with a suitable acid such as dilute one
  • hydroxycarboxylic acids of the general formula V required as starting compounds are obtained by reacting piperidines of the general formula VII
  • Y 1 and Y 2 denote nucleofuge groups which may be identical or different, preferably the chlorine atom, the p-nitrophenoxy or trichloromethoxy group,
  • R 2 is defined as mentioned above and Z 1 represents a protective group for a carboxy group, for example a Ci_6-alkyl or an optionally substituted benzyl group, wherein the alkyl groups may be linear or branched and the benzyl group by one or two Methoxy groups can be substituted, available.
  • Z 1 is preferably the methyl, ethyl, tert-butyl or benzyl group.
  • the compounds of the general formula VII are dissolved in a solvent, for example in dichloromethane, THF, pyridine or mixtures thereof, at a temperature between -20 ° C. and 50 ° C. in the presence of a base, for example triethylamine, pyridine or ethyldiisopropylamine, reacted with the carbonic acid derivatives of general formula VIII.
  • a solvent for example in dichloromethane, THF, pyridine or mixtures thereof.
  • a base for example triethylamine, pyridine or ethyldiisopropylamine
  • reaction of these intermediates with compounds of general formula IX is also carried out in one of the abovementioned solvents, and at the abovementioned temperatures, in the presence of a base, such as triethylamine or pyridine, with or without the addition of an activating reagent, e.g. 4-dimethylaminopyridine.
  • a base such as triethylamine or pyridine
  • an activating reagent e.g. 4-dimethylaminopyridine.
  • the compounds of general formula IX may also be reacted by means of a metal hydride, e.g. NaH or KH be deprotonated, in which case the presence of the base or the activating reagent can be dispensed with.
  • a metal hydride e.g. NaH or KH be deprotonated
  • the starting compounds of the formula VII and VIII are either commercially available, known from the literature or can be prepared by methods known from the literature.
  • R 2 is defined as mentioned above, with ⁇ / acetylglycine in acetic anhydride as solvent in the presence of alkali metal acetate, preferably sodium or potassium acetate, at a suitable temperature, preferably at 80 to 130 ° C.
  • alkali metal acetate preferably sodium or potassium acetate
  • R j2 is defined as mentioned at the beginning.
  • alkali borohydrides such as sodium or potassium borohydride can be used.
  • Further reducing agents are chlordialkylboranes, such as chlorodicyclohexylborane.
  • chlorodicyclohexylborane Become chiral Chlordialkylborane, such as B-Chlordiisopinocampheylboran used, the compounds of general formula XIII can be isolated in enantiomerically pure form.
  • the further reaction of compounds of general formula XIII to compounds of general formula IX is carried out in an alcoholic medium, preferably in methanol or ethanol, in the presence of a suitable acid, such as hydrochloric acid.
  • the reaction can be carried out by reaction in alcoholic solvents, preferably methanol, with thionyl chloride.
  • All compounds of the general formula I which contain primary or secondary amino, hydroxy or hydroxycarbonyl functions are preferably obtained from precursors provided with protective groups.
  • Suitable protective groups for amino functions are, for example, a benzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-chlorobenzyloxycarbonyl, 3-chlorobenzyloxycarbonyl, 4-chlorobenzyloxycarbonyl, 4-biphenylyl- ⁇ , ⁇ -dimethylbenzyloxycarbonyl or 3,5-dimethoxy- ⁇ , ⁇ -dimethylbenzyloxycarbonyl group, an alkoxycarbonyl group having a total of 1 to 5 carbon atoms in the alkyl moiety, for example the methoxycarbonyl, ethoxycarbonyl , n-propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, 1-methylpropoxycarbon
  • Suitable protective groups for hydroxy functions are, for example, a trimethylsilyl, triethylsilyl, triisopropyl, tert-butyldimethylsilyl or tert-butyldiphenylsilyl group, a tert-butyl, benzyl, 4-methoxybenzyl or 3,4-dimethoxybenzyl group.
  • the protective group for hydroxycarbonyl functions is, for example, an alkyl group having a total of 1 to 5 carbon atoms, for example methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, allyl, 2,2,2-trichloroethyl -, benzyl or 4-methoxybenzyl group in question.
  • the compounds of the general formula I obtained can, in particular for pharmaceutical applications, be converted into their physiologically acceptable salts with inorganic or organic acids.
  • suitable acids are hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, acetic acid, fumaric acid, succinic acid, Lactic acid, mandelic acid, malic acid, citric acid, tartaric acid or maleic acid into consideration.
  • novel compounds of the formula I if they contain carboxylic acid functions, can be converted into their addition salts with inorganic or organic bases, in particular for the pharmaceutical application, into their physiologically tolerable addition salts.
  • Suitable bases for this purpose for example, sodium hydroxide, potassium hydroxide, ammonia, cyclohexylamine, dicyclohexylamine, ethanolamine, diethanolamine and triethanolamine into consideration.
  • the present invention relates to racemates, provided that the compounds of general formula I have only one chiral element.
  • the application also includes the individual diastereomeric antipode pairs or mixtures thereof, which are present when more than one chiral element is present in the compounds of general formula I, as well as the individual optically active enantiomers which make up the racemates mentioned.
  • the compounds of the invention including their salts, in which one or more hydrogen atoms, for example one, two, three, four or five hydrogen atoms, are replaced by deuterium.
  • novel compounds of the general formula I and their physiologically tolerable salts have valuable pharmacological properties which are based on their selective CGRP antagonistic properties.
  • Another object of the invention are these compounds containing drugs, their use and their preparation.
  • SK-N-MC cells are cultured in "Dulbecco's modified Eagle Medium”. The medium of confluent cultures is removed. The cells are washed twice with PBS buffer (Gibco 041-04190 M), removed by addition of PBS buffer, mixed with 0.02% EDTA, and isolated by centrifugation. After resuspension in 20 ml Balanced Salts Solution [BSS (in mM): NaCl 120, KCl 5.4, NaHCO 3 16.2, MgSO 4 0.8, NaHPO 4 1.0, CaCl 2 1.8, D-glucose 5.5, HEPES 30, pH 7.40]. The cells are centrifuged twice at 100 xg and resuspended in BSS.
  • BSS Balanced Salts Solution
  • the cells are homogenized using an Ultra-Turrax and centrifuged for 10 minutes at 3000 xg. The supernatant is discarded and the pellet recentrifuged and resuspended in Tris buffer (10 mM Tris, 50 mM NaCl, 5 mM MgCl 2 , 1 mM EDTA, pH 7.40) supplemented with 1% bovine serum albumin and 0.1% bacitracin (1 ml / 1000000 cells). The homogenate is frozen at -80 ° C. The membrane preparations are stable under these conditions for more than 6 weeks.
  • the homogenate is diluted 1:10 with assay buffer (50 mM Tris, 150 mM NaCl, 5 mM MgCl 2 , 1 mM EDTA, pH 7.40) and homogenized for 30 seconds with an Ultra-Turrax. 230 ⁇ l of the homogenate are incubated for 180 minutes at room temperature with 50 pM 125 l-iodotyrosyl-calcitonin gene-related peptides (Amersham) and increasing concentrations of the test substances in a total volume of 250 ⁇ l. Incubation is terminated by rapid filtration through polyethyleneimine (0.1%) treated GF / B glass fiber filters using a cell harvester. The protein bound radioactivity is determined using a gamma counter. Non-specific binding is defined as the bound radioactivity after the presence of 1 ⁇ M human CGRP-alpha during the incubation.
  • assay buffer 50 mM Tris, 150 mM NaCl, 5 mM MgCl 2
  • concentration-binding curves The analysis of the concentration-binding curves is carried out by means of a computer-aided non-linear curve fitting.
  • the compounds mentioned in the introduction show IC 50 values ⁇ 1000 nM in the test described.
  • SK-N-MC cells (1 million cells) are washed twice with 250 ⁇ l of incubation buffer (Hanks ' HEPES, 1 mM 3-isobutyl-1-methylxanthine, 1% BSA, pH 7.4) and at 37 ° C for 15 minutes pre-incubated. After addition of CGRP (10 ⁇ l) as agonist in increasing concentrations (10 -11 to 10 -6 M) or additionally of substance in 3 to 4 different concentrations, the mixture is incubated again for 15 minutes.
  • Intracellular cAMP is then extracted by addition of 20 ⁇ l of 1 M HCl and centrifugation (2000 x g, 4 ° C for 15 minutes). The supernatants are frozen in liquid nitrogen and stored at -20 ° C.
  • the cAMP contents of the samples are determined by means of radioimmunoassay (Amersham) and the pA 2 values of antagonistic substances are determined graphically.
  • the compounds of the invention show in the process described in i / rtro test model CGRP-antagonistic properties in a dosage range between 10 ⁇ -12 and 10 -5 M.
  • the compounds according to the invention and their salts with physiologically tolerated acids are thus suitable for the acute and prophylactic treatment of headaches, in particular migraine, cluster headache and tension-type headaches.
  • the compounds according to the invention also have a positive influence on the following diseases: non-insulin-dependent diabetes mellitus ("NIDDM”), cardiovascular diseases, morphine tolerance, Clostridium toxin-induced diarrheal diseases, skin disorders, in particular thermal and radiation-related skin damage including sunburn, skin, prurigo, pruriginous toxidermias as well as severe itching, inflammatory Diseases such as inflammatory joint diseases (osteoarthritis, rheumatoid arthritis, neurogenic arthritis), generalized soft tissue rheumatism (fibromyalgia), neurogenic inflammations of the oral mucosa, inflammatory lung disease, allergic rhinitis, asthma, COPD, diseases that are associated with excessive vasodilation and consequent reduced tissue perfusion , eg shock and
  • NIDDM non-insul
  • the compounds according to the invention have a soothing effect on pain conditions in general.
  • the symptoms of menopausal, caused by vasodilation and increased blood flow hot flushes of estrogen-deficient women and hormone-treated prostate carcinoma patients and castrates is influenced by the CGRP antagonists of the present application preventively and acutely therapeutically favored, this therapy approach is characterized by hormone substitution by side effects.
  • the compounds according to the invention are preferably suitable for the acute and prophylactic treatment of migraine and cluster headache, for the treatment of irritable bowel syndrome (IBS) and for the preventive and acute therapeutic treatment of hot flushes of estrogen-deficient women.
  • IBS irritable bowel syndrome
  • the dosage required to achieve a corresponding effect is expediently when administered intravenously or subcutaneously from 0.0001 to 3 mg / kg
  • Body weight preferably 0.01 to 1 mg / kg body weight, and by oral, nasal or inhalative administration 0.01 to 10 mg / kg body weight, preferably 0.1 to 10 mg / kg body weight, in each case 1 to 3 times a day.
  • Another object of the invention is the use of the compounds of the invention as valuable tools for generating and purifying (affinity chromatography) of antibodies and, after appropriate radioactive labeling, for example by tritiation of suitable precursors, for example by catalytic hydrogenation with trithium or replacement of halogen atoms by tritium, in RIA and ELISA assays and as diagnostic and analytical tools in neurotransmitter research.
  • Possible combinations of agents include antiemetics, prokinetics, neuroleptics, antidepressants, neurokinin antagonists, anticonvulsants, histamine H1 receptor antagonists, ⁇ -blockers, ⁇ -agonists and ⁇ -antagonists, ergot alkaloids, weak analgesics, non-steroidal anti-inflammatory drugs, corticosteroids, calcium Antagonists, 5-HT 1B / i D agonists or other antimigraine agents, which together with one or more inert customary carriers and / or diluents, for example corn starch, lactose, cane sugar, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, Water / ethanol, water / - glycerol, water / sorbitol, water / polyethylene glycol, propylene glycol, cetylstearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or their suitable mixtures,
  • the non-steroidal anti-inflammatory drugs aceclofenac, acemetacin, acetylsalicylic acid, acetaminophen (paracetamol), azathioprine, diclofenac, diflunisal, fenbufen, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, leflunomide, lornoxicam, mefenamic acid are thus used as further active substances , Naproxen, phenylbutazone, piroxicam, sulfasalazine, zomepirac or their pharmaceutically acceptable salts, as well as meloxicam and other selective COX2 inhibitors, such as rofecoxib, valdecoxib, parecoxib, etoricoxib and celecoxib, as well as substances containing earlier or later steps in the prostaglandin Inhibit synthesis
  • CGRP antagonists with vanilloid receptor antagonists e.g. VR-1 antagonists, glutamate receptor antagonists, e.g. mGlu5 receptor antagonists, inGlui receptor antagonists, iGlu ⁇ receptor antagonists, AMPA receptor antagonists, purine receptor blockers, such as e.g. P2X3 antagonists, NO synthase inhibitors, e.g. iNOS inhibitors, calcium channel blockers, e.g. PQ-type blockers, N-type blockers, potassium channel openers, e.g. KCNQ channel openers, sodium channel blockers, e.g. PN3 channel blockers, NMDA receptor antagonists, acid-sensing ion channel antagonists, e.g.
  • bradykinin receptor antagonists such as e.g. Bi receptor antagonists
  • cannabinoid receptors agonists such as e.g. CB2 agonists, CB1 agonists, somatostatin receptor agonists, e.g. sst2 receptor agonists are given.
  • the dose for these active substances is expediently 1/5 of the usually recommended lowest dosage up to 1/1 of the normally recommended dosage, so for example 20 to 100 mg sumatriptan.
  • the compounds according to the invention may be administered either alone or optionally in combination with other active substances for the treatment of migraine intravenously, subcutaneously, intramuscularly, intraarticularly, intrarectally, intranasally, by inhalation, topically, transdermally or orally, in particular aerosol formulations being suitable for inhalation.
  • the combinations may be administered either simultaneously or sequentially.
  • Suitable application forms are, for example, tablets, capsules, solutions, juices, emulsions or inhalable powders or aerosols.
  • the proportion of the pharmaceutically active compound (s) in each case in the range of 0.1 to 90 wt .-%, preferably 0.5 to 50 wt .-% of the total composition, ie in amounts which are sufficient to achieve the above-mentioned dosage range.
  • Oral administration may be in the form of a tablet, as a powder, as a powder in a capsule (e.g., hard gelatin capsule), as a solution or suspension.
  • the active substance combination can be carried out as a powder, as an aqueous or aqueous-ethanolic solution or by means of a propellant gas formulation.
  • compositions are preferably characterized by the content of one or more compounds of the formula I according to the above preferred embodiments.
  • Corresponding tablets can be prepared, for example, by mixing the active substance (s) with known excipients, for example inert diluents, such as calcium carbonate, calcium phosphate or lactose, disintegrants, such as corn starch or alginic acid, binders, such as starch or gelatin, lubricants, such as magnesium stearate or talc, and / or means for obtaining the depot effect, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate.
  • the tablets can also consist of several layers.
  • Coated tablets can accordingly be produced by coating cores produced analogously to the tablets with agents customarily used in tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar.
  • the core can also consist of several layers.
  • the dragee sheath to achieve a depot effect of several layers may consist of the above mentioned in the tablets excipients can be used.
  • Juices of the active compounds or active compound combinations according to the invention may additionally contain a sweetening agent, such as saccharin, cyclamate, glycerol or sugar, and a taste-improving agent, for example flavorings, such as vanillin or orange extract. They may also contain suspending aids or thickening agents, such as sodium carboxymethylcellulose, wetting agents, for example condensation products of fatty alcohols with ethylene oxide, or protective agents, such as p-hydroxybenzoates.
  • the capsules containing one or more active ingredients or combinations of active substances can be prepared, for example, by mixing the active ingredients with inert carriers, such as lactose or sorbitol, and encapsulating them in gelatine capsules.
  • suitable suppositories can be prepared, for example, by mixing with suitable carriers, such as neutral fats or polyethylene glycol or its derivatives.
  • adjuvants there may be mentioned, for example, water, pharmaceutically acceptable organic solvents such as paraffins (e.g., petroleum fractions), oils of vegetable origin (e.g., peanut or sesame oil), mono- or polyfunctional alcohols (e.g., ethanol or glycerin), carriers such as e.g.
  • paraffins e.g., petroleum fractions
  • oils of vegetable origin e.g., peanut or sesame oil
  • mono- or polyfunctional alcohols e.g., ethanol or glycerin
  • carriers such as e.g.
  • ground natural minerals eg kaolins, clays, talc, chalk
  • synthetic minerals eg fumed silica and silicates
  • sugars eg pipe, milk and dextrose
  • emulsifiers eg lignin, liquors, methylcellulose, starch and polyvinylpyrrolidone
  • lubricants eg Magnesium stearate, talc, stearic acid and sodium lauryl sulfate.
  • the tablets may, of course, besides the abovementioned excipients also contain additives such as sodium citrate, calcium carbonate and dicalcium phosphate together with various adjuvants such as starch, preferably potato starch, gelatin and the like. Further, lubricants such as magnesium stearate, sodium lauryl sulfate and talc may be used for tableting.
  • the active ingredients may be added to the abovementioned excipients with various flavor enhancers or dyes. It is likewise preferred if the compounds of the formula I are administered by inhalation, it is particularly preferred if the administration takes place once or twice daily.
  • Suitable inhalable dosage forms are inhalable powders, propellant-containing metered-dose inhalers or propellant-free inhalable solutions which, if appropriate, are present in admixture with conventional physiologically compatible excipients.
  • propellant-free inhalable solutions also includes concentrates or sterile, ready-to-use inhalable solutions.
  • the administration forms which can be used in the context of the present invention will be described in detail in the following part of the description.
  • the following physiologically acceptable excipients can be used to prepare the inhalable powders according to the invention: monosaccharides (eg glucose or arabinose), disaccharides (eg lactose, sucrose, maltose), oligo- and polysaccharides (eg dextrans), polyalcohols (eg sorbitol, Mannitol, XyNt), salts (eg sodium chloride, calcium carbonate) or mixtures of these auxiliaries with one another.
  • mono- or disaccharides are used, wherein the use of lactose or glucose, in particular, but not exclusively in the form of their hydrates, is preferred.
  • Lactose most preferably lactose monohydrate, is used as adjuvant for the purposes of the invention.
  • Propellant-containing inhalation aerosols The propellant-containing aerosols which can be used in the context of the use according to the invention
  • Inhalation aerosols may be dissolved in propellant gas or in dispersed form.
  • the propellant gases which can be used for the preparation of the inhalation aerosols are known from the prior art.
  • Suitable propellant gases are selected from the group consisting of hydrocarbons such as n-propane, n-butane or isobutane and halogenated hydrocarbons.
  • Hydrogens such as preferably fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane.
  • the abovementioned propellant gases can be used alone or in mixtures thereof.
  • propellant gases are fluorinated alkane derivatives selected from TG134a (1,1,1,2-tetrafluoroethane), TG227 (1,1,2,3,3,3-heptafluoropropane) and mixtures thereof.
  • the propellant-containing inhalation aerosols which can be used in the context of the use according to the invention may also contain further constituents, such as co-solvents, stabilizers, surfactants, antioxidants, lubricants and pH-adjusting agents. All of these ingredients are known in the art.
  • Suitable solvents for this purpose are aqueous or alcoholic, preferably ethanolic
  • the solvent may be water only or it may be a mixture of water and ethanol.
  • the solutions or suspensions are adjusted to a pH of from 2 to 7, preferably from 2 to 5, with suitable acids.
  • acids selected from inorganic or organic acids can be used.
  • inorganic acids are hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid and / or phosphoric acid.
  • particularly suitable organic acids are: ascorbic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid and / or propionic acid and others.
  • Preferred inorganic acids are hydrochloric acid, sulfuric acid.
  • acids which already form an acid addition salt with one of the active substances.
  • organic acids ascorbic acid, fumaric acid and citric acid are preferable.
  • mixtures of said acids may also be employed, particularly in the case of acids which, in addition to their acidification properties, also possess other properties, e.g. as flavorings, antioxidants or
  • Cosolvents and / or further auxiliaries can be added to the propellant-free inhalable solutions which can be used in the context of the inventive use.
  • Preferred cosolvents are those which contain hydroxyl groups or other polar groups, for example alcohols - in particular isopropyl alcohol, glycols - in particular propylene glycol, polyethylene glycol, polypropylene glycol, glycol ethers, glycerol, polyoxyethylene alcohols and polyoxyethylene fatty acid esters.
  • auxiliaries and additives in this context any pharmacologically acceptable substance which is not an active ingredient but which can be formulated together with the active ingredient (s) in the pharmacologically suitable solvent in order to improve the qualitative properties of the active ingredient formulation. These substances preferably do not develop any appreciable or at least no undesirable pharmacological effect in the context of the intended therapy.
  • the auxiliaries and additives include, for example, surfactants, such as soybean lecithin, oleic acid, sorbitan esters, such as polysorbates, polyvinylpyrrolidone other stabilizers, complexing agents, antioxidants and / or preservatives, the
  • the additives also include pharmacologically acceptable salts such as sodium chloride as isotonants.
  • the preferred excipients include antioxidants, such as ascorbic acid, if not already for the
  • Preservatives may be used to protect the formulation from contamination by germs. Suitable preservatives are those known in the art, in particular cetylpyridinium chloride, benzalkonium chloride or benzoic acid or benzoates such as sodium benzoate in the concentration known from the prior art.
  • ready-to-use packs of a medicament for the treatment of respiratory disorders including an enclosed description containing, for example, the words respiratory disease, COPD or asthma, a pteridine and one or more combination partners selected from the group described above, are provided.
  • the ratios indicated for the flow agents relate to volume units of the respective solvents.
  • the indicated volume units at NH 3 refer to a concentrated solution of NH 3 in water.
  • the acid, base and salt solutions used in the workup of the reaction solutions are aqueous systems of the indicated
  • silica gel from Millipore (MATREX TM, 35-70 ⁇ m) is used.
  • HPLC data are measured under the following parameters:
  • Analytical column Zorbax column (Agilent Technologies), SB (stable bond) C18; 3.5 ⁇ m; 4.6 x 75 mm; Column temperature: 30 ° C; Flow: 0.8 mL / min; Injection volume: 5 ⁇ L; Detection at 254 nm
  • Analytical column Zorbax column (Agilent Technologies), SB (stable bond) C18; 3.5 ⁇ m; 4.6 x 75 mm; Column temperature: 30 ° C; Flow: 1.6 ml_ / min; Injection volume: 5 ⁇ l_; Detection at 254 nm
  • Analytical column Zorbax column (Agilent Technologies), SB (stable bond) C18; 3.5 ⁇ m; 4.6 x 75 mm; Column temperature: 30 ° C; Flow: 1.6 ml_ / min; Injection volume: 5 ⁇ l_; Detection at 254 nm
  • Example 1g The product was analogously to Example 1g starting from 8.16 g (13.65 mmol) of 4- (2-oxo-1, 2,4,5-tetrahydro-1, 3-benzdiazepin-3-yl) piperidine-1-carboxylic acid ( R) -2- (4-benzyloxy-3-methoxy-5-methylphenyl) -1-methoxycarbonyl ethyl ester.
  • the precipitate was filtered off with suction, the filtrate i.vac. concentrated and mixed with 800 ml_ DCM and 800 ml_ water.
  • the organic phase was separated, filtered off with suction through Na 2 SO 4 , the solvent i.vac. removed, the residue stirred with EtOAc, filtered off with suction and i. vac dried.
  • the reaction mixture was made alkaline at 0 ° C with 70 ml_ 1 M NaOH, mixed with 100 mL MTBE, stirred for 15 min and the phases were separated.
  • the organic phase was washed with 50 ml of water and three times with 50 ml of 1 M NaOH each time.
  • the combined aqueous phases were washed with half-conc. HCl, extracted exhaustively with EtOAc and dried the combined organic phases over Na 2 SO 4 . After removal of the drying and solvent, the residue was further reacted without purification.
  • Composition 1 capsule for powder inhalation contains: active ingredient 1.0 mg lactose 20.0 mg
  • the active substance is ground to the particle size required for inhalation.
  • the ground active substance is mixed homogeneously with the milk sugar.
  • the mixture is filled into hard gelatin capsules.
  • Composition 1 stroke contains: Active ingredient 1.0 mg
  • the active substance and benzalkonium chloride are dissolved in water and dissolved in Respimat ® -
  • 1 vial contains:
  • Active substance sodium chloride and benzalkonium chloride are dissolved in water.
  • 1 stroke contains: active substance 1.0 mg
  • micronized drug is homogeneously suspended in the mixture of lecithin and propellant.
  • the suspension is filled into a pressure vessel with metering valve.
  • the active ingredient and the excipients are dissolved in water and filled into a corresponding container.
  • Dissolve polysorbate 80 sodium chloride, monopotassium dihydrogen phosphate and disodium hydrogen phosphate in water for injections (WfI); Add human serum albumin; Dissolve active ingredient with heating; fill with WfI on batch volume; fill in ampoules.
  • composition Active substance 10 mg
  • Preparation Dissolve mannitol in water for injection (WfI); Add human serum albumin; Dissolve active ingredient with heating; fill with WfI on batch volume; Fill into ampoules under nitrogen fumigation.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention a pour objet les antagonistes CGRP de formule générale (I) dans laquelle R<SUP>1</SUP>, R<SUP>2</SUP>, R<SUP>3</SUP>, R<SUP>4</SUP> et R<SUP>5</SUP> sont tels que définis dans la revendication 1, leurs tautomères, leurs isomères, leurs diastéréomères, leurs énantiomères, leurs hydrates, leurs mélanges et leurs sels, ainsi que les hydrates des sels, en particulier leurs 10 sels physiologiquement compatibles, avec des acides ou des bases inorganiques ou organiques, ainsi que les composés de formule générale (I), dans lesquels un ou plusieurs atomes d'hydrogène sont remplacés par du deutérium. L'invention concerne en outre des médicaments contenant ces composés, leur utilisation et leur procédé de fabrication.
EP06793855A 2005-09-29 2006-09-27 Antagonistes cgrp selectionnes, leur procede de fabrication et leur utilisation comme medicaments Withdrawn EP1931646A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06793855A EP1931646A2 (fr) 2005-09-29 2006-09-27 Antagonistes cgrp selectionnes, leur procede de fabrication et leur utilisation comme medicaments

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05021282A EP1770087A1 (fr) 2005-09-29 2005-09-29 Antagonistes CGRP selectionnés, leur procedé de préparation ainsi que leur utilisation comme medicaments
EP06793855A EP1931646A2 (fr) 2005-09-29 2006-09-27 Antagonistes cgrp selectionnes, leur procede de fabrication et leur utilisation comme medicaments
PCT/EP2006/066789 WO2007036533A2 (fr) 2005-09-29 2006-09-27 Antagonistes cgrp selectionnes, leur procede de fabrication et leur utilisation comme medicaments

Publications (1)

Publication Number Publication Date
EP1931646A2 true EP1931646A2 (fr) 2008-06-18

Family

ID=36099803

Family Applications (2)

Application Number Title Priority Date Filing Date
EP05021282A Withdrawn EP1770087A1 (fr) 2005-09-28 2005-09-29 Antagonistes CGRP selectionnés, leur procedé de préparation ainsi que leur utilisation comme medicaments
EP06793855A Withdrawn EP1931646A2 (fr) 2005-09-29 2006-09-27 Antagonistes cgrp selectionnes, leur procede de fabrication et leur utilisation comme medicaments

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP05021282A Withdrawn EP1770087A1 (fr) 2005-09-28 2005-09-29 Antagonistes CGRP selectionnés, leur procedé de préparation ainsi que leur utilisation comme medicaments

Country Status (3)

Country Link
US (1) US20080280887A1 (fr)
EP (2) EP1770087A1 (fr)
WO (1) WO2007036533A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
PE20080153A1 (es) * 2006-06-08 2008-04-14 Boehringer Ingelheim Int Composicion farmaceutica que comprende un antagonista del peptido relacionado con el gen calcitonina (cgrp)
DE102006039038A1 (de) 2006-08-19 2008-02-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neues Herstellungsverfahren
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
CN115704811B (zh) * 2022-12-26 2023-03-31 南京威凯尔生物医药科技有限公司 一种高效液相色谱法检测乌布吉泮及其对映体和非对映体杂质的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3483893B2 (ja) 1996-09-10 2004-01-06 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング 修飾アミノ酸、これらの化合物を含む薬物及びそれらの調製方法
DE10250080A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10300973A1 (de) 2003-01-14 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007036533A2 *

Also Published As

Publication number Publication date
US20080280887A1 (en) 2008-11-13
EP1770087A1 (fr) 2007-04-04
WO2007036533A2 (fr) 2007-04-05
WO2007036533A3 (fr) 2007-06-07

Similar Documents

Publication Publication Date Title
EP1770091A1 (fr) Antagonistes CGRP, leur procédé de préparation ansi que leur utilisation comme médicaments
DE102005050892A1 (de) Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1931647A2 (fr) Antagonistes de cgrp selectionnes, procede pour les preparer et leur utilisation comme agents pharmaceutiques
EP1737864A1 (fr) Antagonistes du cgrp selectionnes, leurs procedes de production et leur utilisation comme medicament
EP1737842B1 (fr) Antagonistes cgrp selectionnes, leur procede de production et leur utilisation comme medicaments
EP2438067B1 (fr) Spirolactames comme antagonistes du cgrp
DE102005050953A1 (de) Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
WO2005084672A1 (fr) Antagonistes de cgrp selectionnes, procedes de fabrication et utilisation en tant que medicament
EP1737860A1 (fr) Antagonistes cgrp selectionnes, leur procede de production et leur utilisation comme medicaments
DE102004019492A1 (de) Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1228059B1 (fr) Nouveaux cyclopropanes utilises comme antagonistes de cgrp, medicaments contenant lesdits composes et procedes permettant de les preparer
EP1931646A2 (fr) Antagonistes cgrp selectionnes, leur procede de fabrication et leur utilisation comme medicaments
EP1863791B1 (fr) 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepine-3-yl-piperidines constituant des antagonistes de cgrp
EP2225236B1 (fr) Composés organiques
WO2009034028A2 (fr) Nouveaux composés
WO2007028812A2 (fr) Antagonistes cgrp selectionnes, leur procede de production et leur utilisation comme medicaments
DE102004010254A1 (de) Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080429

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100401